Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.